<DOC>
	<DOCNO>NCT02979821</DOCNO>
	<brief_summary>In trial , treatment efficacy safety Poziotinib assess patient stage IV lung adenocarcinoma harbor HER2 mutation .</brief_summary>
	<brief_title>Poziotinib Stage IV Lung Adenocarcinoma With HER2 Mutation ( KASTT001 )</brief_title>
	<detailed_description>This study design multi-center , open-label , single-arm , prospective , phase II trial patient stage IV lung adenocarcinoma HER2 mutation receive prior EGFR-TKI . Approximately 47 patient enrolled trial , expect study duration 36 month IRB Korea : MFDS approval date . The study drug ( poziotinib ) administer orally one 12 mg tablet day disease progression manifestation unacceptable toxicity . The initial dose study drug 12 mg daily reduce 8 mg daily accord dose reduction criterion protocol . A cycle study treatment define 28 day .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>1. lung adenocarcinoma , stage IV 2 . Patients HER2 mutation sequence Confirmed triplenegative patient remnant tumor DNA 3 . Patients histories previous exposure least one systemic chemotherapy ( EGFRTKI ) 4 . ECOG performance status 0~2 5 . Patient least one measurable lesion accord RECIST 6 . Patients proper organ function follow Neutrophil count : &gt; 1,500/uL Platelet count : &gt; 100,000/uL Hb : &gt; 9.0g/dL AST/ALT : &lt; 2.0 x upper normal limit Bilirubin : &lt; 1.25 x upper normal limit Serum creatinine : &lt; upper normal limit 1 . Expected lie expectancy &lt; 3 month 2 . CNS metastasis spinal cord compression treat operation and/or radiation therapy ( , Patient medically stable condition operation and/or radiation therapy , without symptomatic metastasis brain accordance investigator 's judgment could participate study ) 3 . Patients severe unstable systemic disease accordance investigator 's judgment ( ex , unstable uncompensated respiratory , cardiac , hepatic renal disease ) 4 . Patients histories previous exposure EGFRTKI</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pan-HER inhibitor</keyword>
</DOC>